Cortés-Vicente, E, Guerrero, A, Díaz, C, Martínez, E, Toja-Camba, FJ, Abad, MR, Serra, JM, Trillo, JL, Machín, CM, Gil, A. Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis (Jan, 10.1007/s12325-026-03490-x, 2026). ADVANCES IN THERAPY. 2026; 43(5)DOI:10.1007/s12325-026-03532-4. PMID:41817916. IF:4.000(Q1/3D).

Behrens, GMN, Assoumou, L, Liegeon, G, Antinori, A, Micán, R, Genderini, FG, Post, FA, Rockstroh, JK, Hamzah, L, Domingo, P, Curran, A, Laguno, M, Fletcher, C, Moody, J, Pozniak, A. Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial. LANCET INFECTIOUS DISEASES. 2026; 26(5)DOI:10.1016/S1473-3099(25)00681-4. PMID:41344354. IF:31.000(Q1/1D).

Novello, S, Rabinovich, NM, Shih, JY, Pelizzari, G, Stevenson, J, Majem, M, Ferreira, CG, Petty, WJ, Arriola, E, Castagneris, N, De Castro, J, Morbeck, I, Bauman, J, Toschi, L, Zer, A, Metro, G, Kalmadi, S, Martinez, AA, Al Husaini, H, Meloni, AR, Nduka, C, Ardito-Abraham, C, Xia, CH, Awad, MM. Sotorasib in Advanced KRAS G12C-Mutated NSCLC Results From the Global Expanded Access Program Including Patients With Poor Performance Status and a History of CNS Metastases. Jto Clinical And Research Reports. 2026; 7(5)DOI:10.1016/j.jtocrr.2026.100974. PMID:42006282. IF:(Q/D).

Espinosa, E, Berciano-Guerrero, MA, Muñoz-Couselo, E, Puértolas, T, Manzano, JL, Soria, A, De Miguel, PA, Crespo, G, Sanz, LG, Cerezuela-Fuentes, P, de la Rosa, CA, Majem, M, Castaño, AG, Berrocal, A, Arroyo, FRG, de la Borbolla, MR, Bellido, L, Martínez, JM, Fernández, LA, Carnicero, AM, Castro, RL, Rodríguez, AB, Lecumberri, MJ, Guzmán, JCV, Balea, BC, Rodríguez, JF, Bautista, JV, Pérez, VN, Mujika, K, Subias, MC, Hernández, B, Algarra, SM, Márquez-Rodas, I. Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801. Clinical & Translational Oncology. 2026; 28(5)DOI:10.1007/s12094-025-04098-3. PMID:41313559. IF:2.500(Q3/6D).